Acadian Asset Management LLC Increases Stock Position in Fate Therapeutics, Inc. $FATE

Acadian Asset Management LLC increased its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 67.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,473,565 shares of the biopharmaceutical company's stock after purchasing an additional 999,773 shares during the period. Acadian Asset Management LLC owned 2.16% of Fate Therapeutics worth $1,952,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. raised its position in shares of Fate Therapeutics by 38.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 2,203,323 shares of the biopharmaceutical company's stock worth $1,741,000 after purchasing an additional 616,336 shares during the last quarter. Nuveen LLC acquired a new position in shares of Fate Therapeutics during the 1st quarter worth approximately $300,000. Squarepoint Ops LLC raised its holdings in Fate Therapeutics by 154.2% in the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 20,805 shares during the last quarter. Millennium Management LLC raised its holdings in Fate Therapeutics by 28.9% in the 4th quarter. Millennium Management LLC now owns 413,192 shares of the biopharmaceutical company's stock valued at $682,000 after acquiring an additional 92,576 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Fate Therapeutics by 65.2% in the 4th quarter. BNP Paribas Financial Markets now owns 287,711 shares of the biopharmaceutical company's stock valued at $475,000 after acquiring an additional 113,563 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Fate Therapeutics Stock Down 0.5%

Shares of NASDAQ FATE opened at $0.95 on Wednesday. Fate Therapeutics, Inc. has a 52-week low of $0.66 and a 52-week high of $4.20. The firm has a fifty day moving average of $1.09 and a 200-day moving average of $1.10. The stock has a market capitalization of $109.64 million, a PE ratio of -0.66 and a beta of 2.21.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. The company had revenue of $1.91 million during the quarter, compared to analysts' expectations of $1.16 million. Equities research analysts expect that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Analysts Set New Price Targets

FATE has been the subject of several analyst reports. Wall Street Zen upgraded Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, August 18th. Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Finally, Wells Fargo & Company cut their price target on Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating for the company in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $3.30.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.